BIO International 2025: CEO Paul Hastings discusses the progress Nkarta is making on its NK cell approach to autoimmune conditions episode artwork

EPISODE · Jun 17, 2025 · 9 MIN

BIO International 2025: CEO Paul Hastings discusses the progress Nkarta is making on its NK cell approach to autoimmune conditions

from BiotechTV - News · host BiotechTV

He describes why he believes NK cells are better suited thank T-cells for autoimmune, and updates us on the company's clinical programs. Nkarta will share a data on everything before the end of the year.

Episode metadata supplied by the publisher feed · Published Jun 17, 2025

Embed this episode

NOW PLAYING

BIO International 2025: CEO Paul Hastings discusses the progress Nkarta is making on its NK cell approach to autoimmune conditions

0:00 9:21

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

No similar episodes found.

No similar podcasts found.

Frequently Asked Questions

How long is this episode of BiotechTV - News?

This episode is 9 minutes long.

When was this BiotechTV - News episode published?

This episode was published on June 17, 2025.

Can I download this BiotechTV - News episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.
URL copied to clipboard!